COMMUNIQUÉS West-GlobeNewswire

Symphogen A/S: Symphogen presents promising results from a randomized Phase 2 study with Sym004 at ESMO 2017 Congress
31/08/2017
Symphogen presents promising results from a randomized Phase 2 study with Sym004 at ESMO 2017 Congress Oral presentation of efficacy and safety data of Sym004 in refractory metastatic colorectal cancer COPENHAGEN, [...]
ESPERITE (ESP): L1 Capital subscribes to the Seventh tranche of investment today
31/08/2017
Zutphen, The Netherlands, 31 August 2017 Esperite N.V. (Euronext: ESP, "Esperite" or "the Group") announces that today the Seventh Tranche of EUR 250,000 is issued as a private placement of 25 convertible notes (the " [...]
Biocartis Group NV: Biocartis announces 2017 half-year results on 7 September 2017
31/08/2017
PRESS RELEASE - REGULATED INFORMATION Thursday, 31 August 2017, 07:01 CEST BIOCARTIS ANNOUNCES 2017 HALF-YEAR RESULTS ON 7 SEPTEMBER 2017 Mechelen, Belgium , 31 August 20 17 - Biocartis Group NV (the 'Company' or ' [...]
Biocartis Group NV: Strong performance data of proprietary MSI Biomarkers for the Idylla(TM) MSI Test to be published at ESMO
31/08/2017
PRESS RELEASE: 31 August 2017, 07:00 CEST Strong performance data of proprietary MSI Biomarkers for the Idylla(TM) MSI Test to be published at ESMO Mechelen, Belgium, 31 August 2017 - Biocartis Group NV (the 'Company' [...]
Probiodrug reports financial results for H1 2017 and corporate update
31/08/2017
Probiodrug reports financial results for H1 2017 and corporate update PQ912 delivers positive pharmacodynamic and efficacy results in a Phase-2a study in early stage AD patients Successful settlement of long-pending tax [...]
MDxHealth Announces First Half 2017 Financial Results
31/08/2017
Total revenue up 87%, product revenue up 10% and 44% increase in test volume NEWS RELEASE / REGULATED INFORMATION / INSIDE INFORMATION IRVINE, CA, and HERSTAL, BELGIUM - 07:00 CEST, August 31, 2017 - MDxHealth SA ( [...]
MDxHealth publie ses résultats financiers pour le premier semestre 2017
31/08/2017
Augmentation des recettes totales de 87 %, des recettes du produit de 10 % et 44 % de volume de tests en plus COMMUNIQUÉ DE PRESSE / INFORMATIONS RÉGLEMENTÉES / INFORMATION PRIVILEGIEE IRVINE, CA, et HERSTAL, BELGIQUE [...]
Vistin Pharma ASA : Second quarter 2017 results - continuing strong demand for metformin
31/08/2017
Norwegian pharmaceutical company Vistin Pharma ASA (OSE: VISTIN) experienced strong demand and stable prices for its metformin products in the second quarter of 2017. Upon completion of the recently announced sale of [...]
VALNEVA : Résultats financiers solides & Progrès R&D majeurs au S1 2017
31/08/2017
Valneva: Résultats financiers solides & Progrès R&D majeurs au S1 2017 La société poursuit sa forte performance commerciale tout en se concentrant sur l'avancée de ses principaux programmes de R&D Résultats [...]
VALNEVA: Reports Robust H1 2017 Financial Results & Major R&D Progress
31/08/2017
Valneva Reports Robust H1 2017 Financial Results & Major R&D Progress Company Continues Delivering Strong Commercial Performance while Focusing on Advancing Leading R&D Programs Robust H1 2017 Financial [...]
Santhera Announces Approval of Raxone® for LHON in Israel
31/08/2017
Liestal, Switzerland, August 31, 2017 - Santhera Pharmaceuticals (SIX: SANN) announces approval of Raxone ® (idebenone) for the treatment of visual impairment in adolescent and adult patients with Leber's hereditary [...]
Bone Therapeutics announces H1 results for 2017
31/08/2017
Regulated information The interim financial report is prepared in accordance with article 13 of the Royal Decree on the obligations of issuers of financial instruments admitted to trading on a regulated market and can [...]
Bone Therapeutics publie ses résultats du premier semestre 2017
31/08/2017
Information réglementée Le rapport semestriel est préparé conformément au prescrit de l'article 13 de l'Arrêté Royal relatif aux obligations des émetteurs d'instruments financiers admis à la négociation sur un marché [...]
Bone Therapeutics appoints Jean-Luc Vandebroek as Chief Financial Officer
31/08/2017
Regulated information Bone Therapeutics appoints Jean-Luc Vandebroek as Chief Financial Officer Wim Goemaere to remain as a Non-Executive Director Gosselies, Belgium, 31 August 2017, 7am CEST - BONE THERAPEUTICS ( [...]
Bone Therapeutics nomme Jean-Luc Vandebroek au poste de Directeur financier
31/08/2017
Information réglementée Bone Therapeutics nomme Jean-Luc Vandebroek au poste de Directeur financier Wim Goemaere devient Administrateur non exécutif Gosselies, Belgique, le 31 août 2017, 7h00 CET - BONE THERAPEUTICS ( [...]
Merus participera à deux conférences Investisseurs en septembre 2017
30/08/2017
UTRECHT, Pays-Bas, le 30 août 2017 (GLOBE NEWSWIRE) - Merus N.V. (Nasdaq : MRUS), une entreprise d'immuno-oncologie de stade clinique qui développe des traitements innovants à base d'anticorps bispécifiques (Biclonics [...]
Novartis receives first ever FDA approval for a CAR-T cell therapy, Kymriah(TM) (CTL019), for children and young adults with B-cell ALL that is refractory or has relapsed at least twice
30/08/2017
Media Release (PDF) This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients. The issuer of this announcement warrants that they are solely responsible for the [...]
ObsEva SA to Attend Baird Global Healthcare Conference and Rodman & Renshaw Annual Global Investment Conference in NYC
30/08/2017
Geneva, Switzerland and Boston, MA - 30 August, 2017 - ObsEva SA (NASDAQ: OBSV), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions [...]
Merus to Participate in Two Investor Conferences in September 2017
30/08/2017
UTRECHT, The Netherlands, Aug. 30, 2017 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics (Biclonics®), today announced that [...]

Pages